DK3265126T3 - Kombinationsformulering af tesofensin og metoprolol - Google Patents

Kombinationsformulering af tesofensin og metoprolol Download PDF

Info

Publication number
DK3265126T3
DK3265126T3 DK16711521.1T DK16711521T DK3265126T3 DK 3265126 T3 DK3265126 T3 DK 3265126T3 DK 16711521 T DK16711521 T DK 16711521T DK 3265126 T3 DK3265126 T3 DK 3265126T3
Authority
DK
Denmark
Prior art keywords
tesofensin
metoprolol
combination formulation
formulation
combination
Prior art date
Application number
DK16711521.1T
Other languages
English (en)
Inventor
Peter G Nielsen
Mikael S Thomsen
Bent Højgaard
Original Assignee
Saniona As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saniona As filed Critical Saniona As
Application granted granted Critical
Publication of DK3265126T3 publication Critical patent/DK3265126T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
DK16711521.1T 2015-03-03 2016-03-02 Kombinationsformulering af tesofensin og metoprolol DK3265126T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201570117 2015-03-03
DKPA201570644 2015-10-09
PCT/DK2016/050058 WO2016138908A1 (en) 2015-03-03 2016-03-02 Tesofensine, beta blocker combination formulation

Publications (1)

Publication Number Publication Date
DK3265126T3 true DK3265126T3 (da) 2021-09-13

Family

ID=55589632

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16711521.1T DK3265126T3 (da) 2015-03-03 2016-03-02 Kombinationsformulering af tesofensin og metoprolol

Country Status (33)

Country Link
US (6) US10231951B2 (da)
EP (1) EP3265126B1 (da)
JP (1) JP6772430B2 (da)
KR (1) KR101999463B1 (da)
CN (1) CN107666913B (da)
AU (1) AU2016228002B2 (da)
CA (1) CA2977415A1 (da)
CL (1) CL2017002214A1 (da)
CO (1) CO2017009930A2 (da)
CR (1) CR20170447A (da)
DK (1) DK3265126T3 (da)
DO (1) DOP2017000219A (da)
EA (1) EA033298B1 (da)
EC (1) ECSP17059323A (da)
ES (1) ES2885437T3 (da)
GT (1) GT201700194A (da)
HK (1) HK1247127A1 (da)
HR (1) HRP20211361T1 (da)
HU (1) HUE055974T2 (da)
IL (1) IL254179B (da)
LT (1) LT3265126T (da)
MA (1) MA41634B1 (da)
MX (1) MX2017011257A (da)
PE (1) PE20180187A1 (da)
PH (1) PH12017501509B1 (da)
PL (1) PL3265126T3 (da)
PT (1) PT3265126T (da)
RS (1) RS62275B1 (da)
SA (1) SA517382209B1 (da)
SG (1) SG11201706899VA (da)
SI (1) SI3265126T1 (da)
UA (1) UA122224C2 (da)
WO (1) WO2016138908A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2864264C (en) * 2012-02-16 2020-05-05 Neurosearch A/S Pharmaceutical compositions for combination therapy
US20190060301A1 (en) * 2016-01-15 2019-02-28 Saniona A/S Tesofensine and metoprolol for treatment of hypertension
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020144146A1 (en) * 2019-01-07 2020-07-16 Saniona A/S Tesofensine for reduction of body weight in prader-willi patients
CA3176183A1 (en) 2020-04-22 2021-10-28 Jorgen Drejer Treatment of hypothalamic obesity

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0576617T3 (da) 1991-03-18 1996-12-30 Sepracor Inc Præparat og fremgangsmåde indeholdende optisk rent (S) metoprolol
ZA971525B (en) 1996-02-22 1997-10-21 Neurosearch As Tropane derivatives, their preparation and use.
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
AU2003282375A1 (en) 2003-02-05 2004-08-30 Ipca Laboratories Limited Pharmaceutical compositions and process of production thereof
NZ542097A (en) 2003-04-29 2008-12-24 Pfizer Ltd 5,7-Diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
CA2553649A1 (en) 2004-01-22 2005-08-04 Neurosearch A/S Compounds for the sustained reduction of body weight
DE102005034351A1 (de) 2005-07-22 2007-01-25 Sension, Biologische Detektions- Und Schnelltestsysteme Gmbh Farb-Umschlag-Indikator zur Statusanzeige von RFID-Tickets und -Etiketten
US20070053983A1 (en) 2005-09-06 2007-03-08 Girish Jain Extended release compositions of metoprolol succinate
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
US20090068260A1 (en) * 2006-02-24 2009-03-12 Tomer Gold Beta-1-selective adrenoceptor blocking agent compositions and methods for their preparation
PL1842534T3 (pl) * 2006-02-24 2012-05-31 Teva Pharma Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania
US8815285B2 (en) 2006-03-28 2014-08-26 Wockhardt Ltd. Extended release dosage forms of metoprolol
DE102006020604A1 (de) 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
BRPI0714586A2 (pt) 2006-07-28 2013-05-07 Farmaprojects S A formulaÇço farmacÊutica de liberaÇço prolongada de metropolol e processo para a sua preparaÇço
WO2009065845A1 (en) 2007-11-20 2009-05-28 Neurosearch A/S A method for treating over-eating disorders
WO2009080693A2 (en) * 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker
EP2237781A2 (en) 2007-12-20 2010-10-13 NeuroSearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity
US20100305213A1 (en) 2007-12-27 2010-12-02 Bayer Animal Health Gmbh Treatment of heart disease using beta-blockers
US9408837B2 (en) 2008-05-28 2016-08-09 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
EP2406253B1 (en) 2009-03-11 2013-07-03 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
JP5827952B2 (ja) 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
SI2496583T1 (sl) 2009-11-02 2015-02-27 Pfizer Inc. Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola
CN102145000A (zh) * 2010-02-06 2011-08-10 赤峰维康生化制药有限公司 一种坎地沙坦酯和美托洛尔复方制剂
CN102198112A (zh) * 2010-03-26 2011-09-28 北京天衡药物研究院 一种渗透泵型控释片及其制备方法
US8235632B2 (en) 2010-05-14 2012-08-07 Illinois Tool Works Inc. Cargo bag valve deflector
CN102762198A (zh) * 2010-05-15 2012-10-31 欢腾生命科学有限公司 多单元组合物
WO2012052834A2 (en) 2010-10-21 2012-04-26 Inventia Healthcare Private Limited Multiple unit particulate system comprising metoprolol succinate
AU2012253834B2 (en) 2011-05-06 2016-06-16 Glaxosmithkline Consumer Healthcare (Uk) Ip Limited Sustained release paracetamol formulations
AU2012277375A1 (en) * 2011-06-29 2014-01-30 Sun Pharmaceutical Industries Limited Multilayered dosage form
US9446032B2 (en) 2011-08-26 2016-09-20 Wockhardt Limited Methods for treating cardiovascular disorders
AU2012349771A1 (en) 2011-12-09 2014-07-03 Wockhardt Limited Methods for treating cardiovascular disorder
CA2864264C (en) 2012-02-16 2020-05-05 Neurosearch A/S Pharmaceutical compositions for combination therapy
IN2012DE00826A (da) * 2012-03-21 2015-08-21 Ranbaxy Lab Ltd
CN102626396B (zh) * 2012-04-28 2014-05-07 海南华益泰康药业有限公司 一种美托洛尔缓释片剂及其制备方法
WO2015004617A1 (en) 2013-07-09 2015-01-15 Ranbaxy Laboratories Limited Extended-release pharmaceutical compositions of metoprolol

Also Published As

Publication number Publication date
ECSP17059323A (es) 2018-06-30
LT3265126T (lt) 2021-09-10
UA122224C2 (uk) 2020-10-12
CN107666913B (zh) 2021-11-26
GT201700194A (es) 2019-06-12
WO2016138908A1 (en) 2016-09-09
HRP20211361T1 (hr) 2021-11-26
JP2018507875A (ja) 2018-03-22
AU2016228002B2 (en) 2020-10-01
US20160279067A1 (en) 2016-09-29
SA517382209B1 (ar) 2021-04-19
BR112017018871A2 (pt) 2018-04-17
PT3265126T (pt) 2021-08-30
ES2885437T3 (es) 2021-12-13
CN107666913A (zh) 2018-02-06
US20230092397A1 (en) 2023-03-23
US20180071250A1 (en) 2018-03-15
IL254179A0 (en) 2017-10-31
CR20170447A (es) 2018-03-13
HK1247127A1 (zh) 2018-09-21
DOP2017000219A (es) 2018-02-15
CA2977415A1 (en) 2016-09-09
EA033298B1 (ru) 2019-09-30
US11426383B2 (en) 2022-08-30
US10537551B2 (en) 2020-01-21
RS62275B1 (sr) 2021-09-30
PE20180187A1 (es) 2018-01-23
AU2016228002A1 (en) 2017-09-14
US20180360804A1 (en) 2018-12-20
US10828278B2 (en) 2020-11-10
PH12017501509A1 (en) 2018-02-05
SI3265126T1 (sl) 2021-11-30
MA41634B1 (fr) 2021-09-30
US20200129478A1 (en) 2020-04-30
PL3265126T3 (pl) 2021-12-06
US20210023050A1 (en) 2021-01-28
SG11201706899VA (en) 2017-09-28
JP6772430B2 (ja) 2020-10-21
PH12017501509B1 (en) 2018-02-05
KR20170134393A (ko) 2017-12-06
CO2017009930A2 (es) 2018-01-05
US10231951B2 (en) 2019-03-19
CL2017002214A1 (es) 2018-04-13
KR101999463B1 (ko) 2019-10-01
EP3265126B1 (en) 2021-06-02
EP3265126A1 (en) 2018-01-10
US9579288B2 (en) 2017-02-28
MA41634A (fr) 2018-01-09
HUE055974T2 (hu) 2022-01-28
MX2017011257A (es) 2018-04-10
EA201791875A1 (ru) 2017-12-29
IL254179B (en) 2020-11-30

Similar Documents

Publication Publication Date Title
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3283107T3 (da) Sammensætninger omfattende en kombination af ipilimumab og nivolumab
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3160470T3 (da) Analoger af pridopidin, fremstilling og anvendelse heraf
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3155024T3 (da) Opholdsstrukturer og relaterede fremgangsmåder
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3288553T3 (da) Kombinationer af cannabinoider og n-acylethanolaminer
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3280839T3 (da) Indretning til fremføring og spredning af stofstykker
DK3178324T3 (da) Mikrobicid og fremgangsmåde til fremstilling af samme
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
DK3307267T3 (da) Behandling af multipel sklerose
DK3319609T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer
DK3261644T3 (da) Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning
DK3265126T3 (da) Kombinationsformulering af tesofensin og metoprolol